Radiofrequency Ablation of Intrahepatic Cholangiocarcinoma: Preliminary Experience
Tóm tắt
The purpose of this study was to evaluate the safety and efficacy of percutaneous ultrasound (US)-guided radiofrequency ablation (RFA) in patients with intrahepatic cholangiocarcinoma (ICCA) in a small, nonrandomized series. From February 2004 to July 2008, six patients (four men and two women; mean age 69.8 years [range 48 to 83]) with ICCA underwent percutaneous US-guided RFA. Preintervetional transarterial embolization was performed in two cases to decrease heat dispersion during RFA in order to increase the area of ablation. The efficacy of RFA was evaluated using contrast-enhanced dynamic computed tomography (CT) 1 month after treatment and then every 3 months thereafter. Nine RFA sessions were performed for six solid hepatic tumors in six patients. The duration of follow-up ranged from 13 to 21 months (mean 17.5). Posttreatment CT showed total necrosis in four of six tumors after one or two RFA sessions. Residual tumor was observed in two patients with larger tumors (5 and 5.8 cm in diameter). All patients tolerated the procedure, and there with no major complications. Only 1 patient developed post-RFA syndrome (pain, fever, malaise, and leukocytosis), which resolved with oral administration of acetaminophen. Percutaneous RFA is a safe and effective treatment for patients with hepatic tumors: It is ideally suited for those who are not eligible for surgery. Long-term follow-up data regarding local and systemic recurrence and survival are still needed.
Tài liệu tham khảo
The Liver Cancer Study Group of Japan (1984) Primary liver cancer in Japan. Cancer 54:1747–1755
American cancer society. What are the key statistics for bile duct cancer? Available at: www.cancer.org
Yamamoto J, Kosuge T, Takayama T et al (1992) Surgical treatment of intrahepatic cholangiocarcinoma: four patients surviving more than five years. Surgery 111:617–622
Lieser MJ, Barry MK, Rowland C et al (1998) Surgical management of intrahepatic cholangiocarcinoma: A 31-year experience. J Hepatobiliary Pancreat Surg 5:41–47
Chu KM, Lai EC, Al-Hadeedi S et al (1997) Intrahepatic cholangiocarcinoma. World J Surg 21:301–305
Jarnagin WR, Shoup M (2004) Surgical management of cholangiocarcinoma. Semin Liver Dis 24:189–199
Chiou YY, Hwang JI, Chou YH et al (2005) Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J Med Sci 21:304–308
Slakey DP (2002) Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg 68:395–397
Rai R, Manas D, Rose J (2005) Radiofrequency ablation of recurrent cholangiocarcinoma after orthotopic liver transplantation―A case report. World J Gastroenterol 11(4):612–613
Zgodzinski W, Espat NJ (2005) Radiofrequency ablation for incidentally identified primary intrahepatic cholangiocarcinoma. World J Gastroenterol 11(33):5239–5240
Nathan H, Pawlik TM, Wolfgang CL et al (2007) Trends in survival after surgery for cholangiocarcinoma: A 30-year population-based SEER database analysis. J Gastrointest Surg 11:1488–1496
Blechacz B, Gores JG (2008) Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48:308–321
Jarnagin WR, Fong Y, DeMatteo RP et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507–517
Golfieri R, Giampalma E, Renzulli M et al (2006) Unresectable hilar cholangiocarcinoma: Multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy. In Vivo 20:757–760
Shin HS, Seong J, Kim WC et al (2003) Combination of external beam irradiation and high-dose rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Physiol 57:105–112
Qian XJ, Zhai RY, Dai DK et al (2006) Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment. World J Gastroenterol 12(2):331–335
Mambrini A, Guglielmi A, Pacetti P et al (2007) Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Res 27:3009–3013
Gusani N, Balaa F, Steel J et al (2008) Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 12:129–137
Yonemoto N, Furuse J, Okusaka T et al (2007) A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 7:843–851
Aliberti C, Benea G, Tilli M et al (2008) Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 31:883–888
Wood TF, Rose DM, Chung M et al (2000) Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 7:593–600
Goldberg SN, Hahn PF, Tanabe KK et al (1998) Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol 9:101–111
Fan WJ, Wu PH, Zhang L et al (2008) Radiofrequency ablation as a treatment for hilar cholangiocarcinoma. World J Gastroenterol 14(28):4540–4545
Carrafiello G, Laganà D, Ianniello A et al (2007) Post-radiofrequency ablation syndrome after percutaneous radiofrequency of abdominal tumours: one centre experience and review of published works. Australas Radiol 51:550–5504
Khan A, Thomas HC, Davison BR et al (2005) Cholangiocarcinoma. Lancet 366:1303–1314